Role of Sotagliflozin in Managing Heart Failure in Diabetes

A chronic illness that impairs heart function is heart failure. This malfunction can put strain on other organs and be especially dangerous for those who have long-term conditions like diabetes and high blood pressure. Patients with diabetes are more likely to develop heart failure. Sotagliflozin is an oral medication used to treat diabetes. A dual sodium drug called sotagliflozin shows promise in the treatment of heart failure. An essential new family of medications for the treatment of diabetes is the sodium-dependent glucose transporter 2 (SGLT2) inhibitors. The goal of developing SGLT2 inhibitors has been to achieve high SGLT2 protein selectivity compared to SGLT1 protein. Treating diabetes with a single drug that combines the inhibition of SGLT1 and SGLT2 would offer complementing insulin-independent strategies. Thus, sotagliflozin (LX4211) was created as a dual SGLT1 and SGLT2 inhibitor. Large postprandial glucose decrease, increase of glucagon-like peptide 1, and mild urine glucose excretion are the distinguishing clinical aspects of dual inhibitor of SGLT1 and SGLT2. These characteristics might have an impact on how sotagliflozin is used clinically to treat diabetes.